![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1729666
½ÅÀå ÀÌ½Ä ÀÇ·á ½ÃÀå : Á¦Ç° À¯Çüº°, Åõ¿© °æ·Îº°, ÀûÀÀÁõº°, ȯÀÚ ¿¬·Éº°, À¯Åë ä³Îº°, Áö¿ªº°Kidney Transplant Medicine Market, By Product Type, By Route of Administration, By Indication, By Patient Age, By Distribution Channel, By Geography |
¼¼°è ½ÅÀå ÀÌ½Ä ÀÇ·á ½ÃÀåÀº 2025³â 128¾ï 4,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 190¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁö CAGR 5.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í¼ ¹üÀ§ | º¸°í¼ »ó¼¼ | ||
---|---|---|---|
±âÁØ ¿¬µµ | 2024³â | 2025³â ½ÃÀå ±Ô¸ð | 128¾ï 4,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2020-2024³â | ¿¹Ãø ±â°£ | 2025-2032³â |
¿¹Ãø ±â°£ : 2025-2032³â CAGR | 5.80% | 2032³â °¡Ä¡ ¿¹Ãø | 190¾ï 9,000¸¸ ´Þ·¯ |
¼¼°è ½ÅÀå ÀÌ½Ä ÀÇ·á ½ÃÀåÀº Áö³ 10³â°£ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» ÀÌ·ç¾ú½À´Ï´Ù. ½ÅÀå Áúȯ ¹× ½ÅºÎÀü À¯º´·üÀÇ Áõ°¡¿Í ´õºÒ¾î ¸¸¼ºÁúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ÀÇ Áõ°¡·Î ÀÎÇØ ½ÅÀå ÀÌ½Ä ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ½Ä ¾àǰ ¹× ÀÌ½Ä ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÌ½Ä ¼º°ø·ü°ú ÀÌ½Ä ÈÄ °ü¸®ÀÇ ÁúÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ½ÅÀå À̽ÄÀ» Ä¡·á ¿É¼ÇÀ¸·Î °í·ÁÇϴ ȯÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤ºÎ ¹× ¹Î°£ ´ÜüÀÇ Àå±â ±âÁõ ¹× À̽Ŀ¡ ´ëÇÑ ÀÎ½Ä °³¼±¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ÀÌ½Ä ¼ö¼ú ¹× Ä¡·á ÈÄ °ü¸® ºñ¿ëÀÌ ³ô´Ù´Â Á¡Àº À̽ÄÀÇ º¸±ÞÀ» ÀúÇØÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
¼¼°è ½ÅÀå ÀÌ½Ä ÀÇ·á ½ÃÀåÀº ÇâÈÄ 10³â°£ °·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. National Kidney Foundation, Inc.ÀÇ Á¶»ç¿¡ µû¸£¸é, ½ÅºÎÀüÁõ ȯÀÚÀÇ 80% ÀÌ»óÀÌ º¸ÆíÀû ÀǷẸÇèÁ¦µµ°¡ ÀÖ°í °í·ÉȰ¡ ÁøÇà ÁßÀÎ ºÎÀ¯ÇÑ ±¹°¡¿¡¼ Ä¡·á¸¦ ¹Þ°í ÀÖÀ¸¸ç, ½ÅÀå À̽ÄÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ºÎÀ¯ÇÑ ±¹°¡¿¡¼ Ä¡·á¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. Áß±¹À̳ª Àεµ¿Í °°Àº °³¹ßµµ»ó±¹¿¡¼´Â ³ëÀÎ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ȯÀÚ°¡ ±ÞÁõÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ Æ´»õ´Â ÀÌ½Ä ÈÄ Àå±â ±â´ÉÀ» µ½°Å³ª ÀÌ½ÄÆí °ÅºÎ¹ÝÀÀÀ» Áö¿¬½ÃŰ´Â Çõ½ÅÀûÀÎ ÀǾàǰ °³¹ßÀÇ ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¹Ý¸é, ½Å¾à ½ÂÀαîÁö ¼Ò¿äµÇ´Â ±ä ±â°£°ú ÀÌ½Ä ÀǾàǰ °³¹ß¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦°¡ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ¸ÂÃãÇü ºÐÀÚ´Â °í°¡À̱⠶§¹®¿¡ Á¢±ÙÀÌ ½±Áö ¾ÊÀº °ÍÀÌ Çö½ÇÀÔ´Ï´Ù. ±×·¯³ª ¹ÙÀÌ¿À Á¦¾à»çµéÀÇ ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡·Î Á¦Ç° ÆÄÀÌÇÁ¶óÀÎÀÌ ²ÙÁØÈ÷ Áõ°¡ÇÏ¸é¼ 2032³â±îÁö ½ÃÀå ±Ô¸ð°¡ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°èÀÇ ½ÅÀå ÀÌ½Ä ÀÇ·á ½ÃÀåÀ» »ó¼¼È÷ ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â)ÀÇ ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ Ã¢Ãâ ±âȸ¸¦ ÆÄ¾ÇÇϰí, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ½ÇÀû, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ½ÅÀå ÀÌ½Ä ÀÇ·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» ¼ö·ÏÇϰí ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
½ÅÀå ÀÌ½Ä ÀÇ·á ¼¼°è ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ÁøÀÔÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ½ÅÀå ÀÌ½Ä ÀÇ·á ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.
Global Kidney Transplant Medicine Market is estimated to be valued at USD 12.84 Bn in 2025 and is expected to reach USD 19.09 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 12.84 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 5.80% | 2032 Value Projection: | USD 19.09 Bn |
The global kidney transplant medicine market has been witnessing significant growth over the past decade. Rising prevalence of kidney diseases and failure along with growing elderly population who are more prone to such chronic conditions has been driving the demand for kidney transplant procedures. Additionally, advancements in transplant medicines and technologies have improved success rates of transplants and post-transplant care management. This has encouraged more patients to consider kidney transplant as a treatment option. Furthermore, increasing investments by governments and private organizations in creating awareness about organ donation and transplants is also anticipated to boost the market during the forecast period. However, high cost of the overall transplant procedure and post care management remains a major restraint for widespread adoption.
The global kidney transplant medicine market is expected to witness robust growth over the next decade. Growing prevalence of diabetes, hypertension, and other lifestyle diseases have emerged as key drivers for end stage renal diseases, thereby augmenting the need for kidney transplants. As per a study by National Kidney Foundation, Inc., more than 80% of kidney failure patients receive treatment in wealthy countries with universal healthcare and aging populations. Cases are expected to rise sharply in developing nations like China and India due to their growing elderly populations.
This gap has opened opportunities for the development of innovative medicines that aid organ function post transplantation or delay graft rejection. On the other hand, lengthy approval timelines for new drugs and stringent regulations pertaining to transplant medicine development acts as a restraint. Moreover, high cost of these tailor-made molecules limits their accessibility. However, increasing R&D investments by biopharma players is anticipated to steadily increase the product pipeline and, in turn, grow the market size through 2032.
This report provides in-depth analysis of the global kidney transplant medicine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global kidney transplant medicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis, Roche, Astellas Pharma, Bristol-Myers Squibb, AbbVie, Takeda Pharmaceutical Company, Pfizer, Merck & Co., Sanofi, Amgen, Gilead Sciences, Teva Pharmaceutical Industries, Fresenius Medical Care, HLA Typing Solutions, and Celgene Corporation
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global kidney transplant medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global kidney transplant medicine market